Validation of the ProSomnus® RPMO2 Device

Validation of the ProSomnus® RPMO2 Pulse Oximeter Device

The purpose of the study is to:

1. Evaluate the SpO2 accuracy of the oximeter component of the ProSomnus RPMO2 Device during non-motion conditions over the range of 70-100% SaO2 by comparison to SaO2 values determined by arterial blood sample specimen analyzed by a CO-oximeter.
2. Evaluate the pulse rate performance simultaneously collected over the SpO2 range.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Device: ProSomnus RPMO2

Detailed Description

Testing will be performed with participants semi-recumbent, under non-motion conditions. SpO2 accuracy of the test device will be determined by a controlled desaturation study with measurements taken over the full range of SaO2 values for which accuracy is to be claimed +3% of the lower value and -3% of the upper value. Participants will be desaturated to achieve six plateaus between 100-70% SaO2.

Arterial blood draws within the hypoxic plateaus will be performed, with draws occurring no less than 30 seconds after reaching a plateau and no less than 20 seconds apart. Five blood draws will be taken at each plateau. Plateaus will be determined using the reference transmittance pulse oximeter and are defined as a change in SpO2 on the reference pulse oximeter of no more than 1% over a duration of 20 seconds. Sampling will not continue if the blood oxygen saturation destabilizes between blood draws.

Time in low O2 saturation decades (i.e., 70-80% and 80-90%) will be limited to the minimum amount of time required to obtain test data and will not exceed 10 minutes. The saturation level at each plateau and the number of plateaus may vary among participants. Arterial pressure, ECG, heart rate, EtCO2, respiratory rate, and FiO2 will be monitored during testing. Extra samples may be collected at the discretion of the PI. The controlled desaturation protocol is expected to take approximately 30 to 60 minutes.

• Study Type: Observational
• Enrollment (Actual): 12

Contacts and Locations

Study Locations

• Canada
  • Alberta
    • Calgary, Alberta, Canada, T2N4N1
      • University of Calgary

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

The study will include volunteers who have previously been determined to be healthy enough for the study and who have signed an informed consent form and met the eligibility criteria.

A minimum of 10 healthy participants will be recruited to complete the test protocol. A minimum of two participants or 15% of the participant pool (whichever is larger) will have Fitzpatrick Skin type IV, V, or VI (i.e., darkly pigmented skin).

Description

Inclusion Criteria:

• Male or female, aged ≥ 18 and < 50 years.
• In good health with no evidence of medical problems.
• Ability to provide informed consent and willingness to comply with the study procedures.
• Ability to undergo controlled hypoxemia to the levels outlined in the desaturation profile.
• Adequate dentition for an oral appliance.
• Ability to breathe through the nose comfortably.

Exclusion Criteria:

• Obesity (BMI > 40 kg/m2).
• Known history of heart, lung, kidney, or liver disease.
• Diagnosis of asthma or sleep apnea.
• Diagnosis of diabetes.
• Presence of a clotting disorder.
• Presence of hemoglobinopathy or history of anemia that, in the opinion of the PI, makes the individual unsuitable for participation.
• Current smoker.
• History of fainting or vasovagal response.
• History of sensitivity to local anesthesia.
• Unacceptable collateral circulation based on exam (Allen's test).
• Pregnancy or lactation.
• Resting heart rate > 120 bpm.
• Systolic BP > 150, diastolic BP > 90.
• Carboxyhemoglobin level > 3%.
• Presence of any other condition that, in the opinion of the PI, makes the individual unsuitable for participation.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Healthy volunteers; Health adult volunteers will undergo a controlled desaturation to collect data for validation of the RPMO2 device.	Device: ProSomnus RPMO2; The ProSomnus RPMO2 device is an intraoral reflectance pulse oximeter.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
SpO2 accuracy	Root-mean-square (Rms) ± 3.5 [% SpO2] over the range of 70 to 100% SaO2	2 hours
Pulse rate accuracy	Rms within ± 3 [1/min] over the claimed range	2 hours

Collaborators and Investigators

• Sponsor: ProSomnus Sleep Technologies

Study record dates

Study Major Dates

• Study Start (Actual): June 10, 2024
• Primary Completion (Actual): September 15, 2024
• Study Completion (Actual): June 30, 2025

Study Registration Dates

• First Submitted: February 12, 2024
• First Submitted That Met QC Criteria: February 12, 2024
• First Posted (Actual): February 20, 2024

Study Record Updates

• Last Update Posted (Estimated): September 2, 2025
• Last Update Submitted That Met QC Criteria: August 29, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Keywords: pulse oximeter
• Other Study ID Numbers: REB23-1003

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes